Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586692 | 0.88 | TDP1 (0.63) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL714123 | 0.82 | TDP1 (0.57) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL537205 | 0.81 | TDP1 (0.65) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL712632 | 0.81 | LMNA (0.61) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL3829668 | 0.81 | TDP1 (0.55) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL11570127 | 0.80 | RAB9A (0.53) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL11570130 | 0.80 | RAB9A (0.53) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL582352 | 0.79 | TDP1 (0.63) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL194520 | 0.79 | TDP1 (0.63) | RAB9ANPC1HPGDTDP1ALDH1A1 | |
| SCHEMBL31420198 | 0.79 | TDP1 (0.63) | RAB9ANPC1HPGDTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384629-B | Photochromic compositions and articles containing siloxane, alkylene, or substituted alkylene oligomers | POLYMERS AUSTRALIA PTY LTD | 2012-05-16 | — | — | CN | disclosed |
| CN-101087862-B | Photochromic compounds comprising polymeric substituents, process for their preparation and their use | POLYMERS AUSTRALIA PTY LTD | 2011-10-26 | — | — | CN | disclosed |
| CN-101827840-A | Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| US-7528137-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| CN-101384629-A | Photochromic compositions and articles containing siloxane, alkylene, or substituted alkylene oligomers | POLYMERS AUSTRALIA PTY LTD (AU) | 2009-03-11 | — | — | CN | disclosed |
| CN-101087862-A | Photochromic compounds comprising polymeric substituents, process for their preparation and their use | POLYMERS AUSTRALIA PTY LTD (AU) | 2007-12-12 | — | — | CN | disclosed |
| US-7214800-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1553931-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060094735-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1553931-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040077668-A1 | Compounds, compositins, and methods | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003097053-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077668-A1 | Compounds, compositins, and methods | CEP170, PSAP, PACSIN2 | RAB9A 4310/4885NPC1 1720/4885HPGD 1813/4885 |
| US-20060094735-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | RAB9A 2407/4885NPC1 366/4885HPGD 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.